Peapod Lane Capital LLC Acquires Shares of 428,904 Seer, Inc. (NASDAQ:SEER)

Peapod Lane Capital LLC bought a new position in shares of Seer, Inc. (NASDAQ:SEER - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 428,904 shares of the company's stock, valued at approximately $991,000. Peapod Lane Capital LLC owned 0.73% of Seer as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Palumbo Wealth Management LLC boosted its position in Seer by 15.1% during the 3rd quarter. Palumbo Wealth Management LLC now owns 122,292 shares of the company's stock worth $241,000 after acquiring an additional 16,001 shares during the period. Barclays PLC raised its holdings in shares of Seer by 34.1% during the 3rd quarter. Barclays PLC now owns 64,426 shares of the company's stock valued at $127,000 after purchasing an additional 16,382 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Seer in the second quarter worth about $30,000. Geode Capital Management LLC raised its position in shares of Seer by 5.9% in the third quarter. Geode Capital Management LLC now owns 446,329 shares of the company's stock valued at $879,000 after purchasing an additional 25,002 shares during the period. Finally, Quadrature Capital Ltd lifted its position in Seer by 301.7% during the 3rd quarter. Quadrature Capital Ltd now owns 57,088 shares of the company's stock worth $112,000 after acquiring an additional 42,875 shares during the last quarter. Institutional investors and hedge funds own 75.20% of the company's stock.

Seer Stock Performance

SEER remained flat at $2.31 during midday trading on Monday. The company's stock had a trading volume of 269,349 shares, compared to its average volume of 133,097. The firm has a fifty day simple moving average of $2.34 and a two-hundred day simple moving average of $2.08. The stock has a market capitalization of $136.22 million, a PE ratio of -1.78 and a beta of 1.58. Seer, Inc. has a 12-month low of $1.53 and a 12-month high of $2.63.

Seer Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.